Find Bill
Find Your Legislator
Legislative Deadlines
Dec. 15, 2019
RSS Feed Permanent URL -A +A

Minutes for HB2107 - Committee on Public Health and Welfare

Short Title

Inclusion of biological products in the pharmacy act of the state of Kansas.

Minutes Content for Thu, Mar 16, 2017

Chairperson Schmidt opened the hearing on HB2107.

Scott Abbott, Staff Revisor, gave an overview of the bill.

Proponent testimony was presented by:

Greg Hoke stated that passage of HB2107 would allow pharmacists to substitute biologic products, while assuring that substitution is done with the prescriber's authorization, and with the patient's notification.(Attachment 6)

Dr. Thomas Felix gave a detailed explanation of Biologics (Attachment 7)

Dr. Harry Gewanter urged the passage of HB2107 as it will update Kansas' Pharmacy Act to better allow the safe substitution of biologic medications when appropriate. (Attachment 8)

Sue Hensley testified that HB2107 not only updates the Kansas Pharmacy Practice Act but will also result in access to lower cost drugs for patients throughout Kansas. (Attachment 9)

Staci Penner testified as a proponent for HB2107. Her experiences include being an occupational therapist; someone familiar with arthritis both personally and professionally and as the mother of a young daughter diagnosed with polyarticular juvenile arthritis. She fully supports the passage of HB2107 with the communication component included.(Attachment 10)

Proponent written testimony was submitted by:

Michele Guadalupe, Arthritis Foundation (Attachment 11)

Timothy Shaver, MD, Kansas Rheumatology Alliance (Attachment 12)

Hilary Gee, Cancer Action Network (Attachment 13)

Philip Schneider, Alliance for Safe Biologic Medicine (Attachment 14)

Michael Harrold and Larrie Ann Brown, Express Scripts (Attachment 15)

Eric Stafford, Kansas Chamber of Commerce (Attachment 16)

Lis Houchen, National Association of Chain Drug Stores submitted written testimony with a neutral position. (Attachment 17)

After Committee questions, Chairperson Schmidt stated that the hearing on SB2107 would be continued on March 22, 2017 to allow opponent testimony to be heard.